Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $21.20, for a total transaction of $572,400.00. Following the completion of the transaction, the insider directly owned 112,622 shares in the company, valued at $2,387,586.40. This represents a 19.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adam Crystal also recently made the following trade(s):

• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total value of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $303,765.00.
• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total value of $226,221.52.

Tango Therapeutics Price Performance

Shares of TNGX opened at $21.63 on Friday. Tango Therapeutics, Inc. has a 12 month low of $1.03 and a 12 month high of $22.20. The stock has a fifty day moving average price of $14.94 and a 200 day moving average price of $11.05. The company has a market cap of $3.09 billion, a P/E ratio of -24.86 and a beta of 1.31.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. As a group, research analysts anticipate that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TNGX. Seven Fleet Capital Management LP acquired a new stake in shares of Tango Therapeutics during the 4th quarter valued at $1,906,000. XTX Topco Ltd acquired a new position in shares of Tango Therapeutics in the 4th quarter worth $335,000. VARCOV Co. acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth $261,000. Virtus Investment Advisers LLC raised its position in shares of Tango Therapeutics by 26.3% during the fourth quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock worth $252,000 after purchasing an additional 5,920 shares during the period. Finally, Tudor Investment Corp ET AL lifted its holdings in shares of Tango Therapeutics by 27.4% during the fourth quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock valued at $605,000 after purchasing an additional 14,679 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group began coverage on Tango Therapeutics in a report on Thursday. They set a “buy” rating and a $30.00 price target on the stock. Stifel Nicolaus increased their price objective on Tango Therapeutics from $15.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Guggenheim lifted their target price on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright raised their price target on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a report on Friday, March 6th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tango Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.67.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.